Myriad Genetics (MYGN) Tops Q4 EPS by 4c
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $4.50 -0.88%
Revenue Growth %: -2.7%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -2.7%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of ($0.12), $0.04 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $177.8 million versus the consensus estimate of $169.47 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- Hermès can regain momentum despite China weakness, Jefferies says
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
